Encapsulated engineered myoblasts can cure Hurler syndrome: Preclinical experiments in the mouse model

Gene Therapy

Volumn 19, Issue 4, 2012, Pages 355-364

  Piller Puicher, E ^a   Tomanin, R ^a   Salvalaio, M ^a   Friso, A ^a   Hortelano, G ^b   Marin, O ^a   Scarpa, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

alginate microcapsules; animal model; Hurler syndrome; MPSI; mucopolysaccharidosis; somatic cell therapy

Indexed keywords

ALGINIC ACID; GLYCOSAMINOGLYCAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ENGINEERING; CELL LINE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FOLLOW UP; HURLER SYNDROME; IMMUNE RESPONSE; IMPLANTATION; MICROCAPSULE; MOUSE; MYOBLAST; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; SOMATIC CELL THERAPY;

ALGINATES; ANIMALS; CAPSULES; CELL LINE; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; GENE THERAPY; GLUCURONIC ACID; GLYCOSAMINOGLYCANS; HEXURONIC ACIDS; IDURONIDASE; MICE; MICE, INBRED C57BL; MUCOPOLYSACCHARIDOSIS I; MYOBLASTS; PERITONEUM;

ANIMALIA; MURINAE;

EID: 84859598178     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.94     Document Type: Article

References (31)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease, Vol. 3. McGraw-Hill Professional Publishing: New York, 2001, pp 3421-3452.
2. Illsinger S, Lucke T, Hartmann H, Mengel E, Muller-Forell W, Donnerstag F et al. Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression. J Inherit Metab Dis. Short Report #190 (2009), Published online 4 November 2009; doi:10.1007/s10545- 009-1265-y.
3. Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981; 2: 709-712. (Pubitemid 11061090)
4. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 2003; 31: 229-239. (Pubitemid 36336225)
5. Wraith JE. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties. J Inherit Metab Dis 2001; 24: 245-250. (Pubitemid 32479418)
6. Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 2007; 120: e37-e46. (Pubitemid 47036214)
7. Messina C, Rampazzo A, Cesaro S, Monciotti C, Gasparotto N, Tomanin R et al. Eighteen-year follow-up of the first Italian MPSI patient treated with bone marrow transplantation. Bone Marrow Transplant 2008; 41: 905-906. (Pubitemid 351761693)
8. Clarke LA. Mucopolysaccharidosis Type I. In: Pagon RA, Bird TD, Dolan CR, Stephens K (eds). GeneReviews. University of Washington, Seattle: Seattle (WA), 1993.
9. Platt FM, Lachmann RH. Treating lysosomal storage disorders: current practice and future prospects. Biochim Biophys Acta 2009; 1793: 737-745.
10. Chang PL. Microcapsules as bio-organs for somatic gene therapy. Ann NY Acad Sci 1997; 831: 461-473. (Pubitemid 28045298)
11. Ross CJ, Bastedo L, Maier SA, Sands MS, Chang PL. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther 2000; 11: 2117-2127.
12. Hernandez RM, Orive G, Murua A, Pedraz JL. Microcapsules and microcarriers for in situ cell delivery. Adv Drug Deliv Rev 2010; 62: 711-730.
13. Barsoum SC, Milgram W, Mackay W, Coblentz C, Delaney KH, Kwiecien JM et al. Delivery of recombinant gene product to canine brain with the use of microencapsulation. J Lab Clin Med 2003; 142: 399-413. (Pubitemid 38102024)
14. Friso A, Tomanin R, Alba S, Gasparotto N, Puicher EP, Fusco M et al. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gene Med 2005; 7: 1482-1491. (Pubitemid 41672407)
15. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 2003; 100: 1902-1907. (Pubitemid 36254546)
16. Wen J, Vargas AG, Ofosu FA, Hortelano G. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells. J Gene Med 2006; 8: 362-369.
17. Muenzer J, Fisher A. Advances in the treatment of mucopolysaccharidosis type I. N Engl J Med 2004; 350: 1932-1934. (Pubitemid 38580194)
18. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004; 27: 385-410. (Pubitemid 38756323)
19. Herati RS, Ma X, Tittiger M, Ohlemiller KK, Kovacs A, Ponder KP. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice. J Gene Med 2008; 10: 972-982.
20. Mercimek-Mahmutoglu S, Reilly C, Human D, Waters PJ, Stoeckler-Ipsiroglu S. Progression of organ manifestations upon enzyme replacement therapy in a patient with mucopolysaccharidosis type I/Hurler. World J Pediatr 2009; 5: 319-321.
21. Kakkis ED, Schuchman E, He X, Wan Q, Kania S, Wiemelt S et al. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 2001; 72: 199-208. (Pubitemid 34171436)
22. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance). OJ 2007; L324: 121-137.
23. Food and Drug Administration. Application of current statutory authorities to human somatic cell therapy products and gene therapy products. Fed Regist 1993; 58: 53248-53251.
24. de Vos P, Bucko M, Gemeiner P, Navratil M, Svitel J, Faas M et al. Multiscale requirements for bioencapsulation in medicine and biotechnology. Biomaterials 2009; 30: 2559-2570.
25. Montgomery DL, Shiver JW, Leander KR, Perry HC, Friedman A, Martinez D et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 1993; 12: 777-783. (Pubitemid 24295353)
26. Hortelano G, Al-Hendy A, Ofosu FA, Chang PL. Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood 1996; 87: 5095-5103. (Pubitemid 26189850)
27. Di Domenico C, Villani GR, Di Napoli D, Reyero EG, Lombardo A, Naldini L et al. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. Hum Gene Ther 2005; 16: 81-90. (Pubitemid 40250334)
28. Tomanin R, Friso A, Alba S, Piller Puicher E, Mennuni C, La Monica N et al. Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome). Acta Paediatr Suppl 2002; 91: 100-104. (Pubitemid 36174160)
29. Bjornsson S. Simultaneous preparation and quantitation of proteoglycans by precipitation with alcian blue. Anal Biochem 1993; 210: 282-291. (Pubitemid 23171019)
30. Whitley CB, Ridnour MD, Draper KA, Dutton CM, Neglia JP. Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem 1989; 35: 374-379. (Pubitemid 19086682)
31. de Jong JG, Wevers RA, Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 1992; 38: 803-807.